Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856193 | ISIN: SE0000112724 | Ticker-Symbol: SCA
Tradegate
24.01.25
14:52 Uhr
12,970 Euro
+0,015
+0,12 %
1-Jahres-Chart
SVENSKA CELLULOSA AB Chart 1 Jahr
5-Tage-Chart
SVENSKA CELLULOSA AB 5-Tage-Chart
RealtimeGeldBriefZeit
12,93512,97024.01.
12,93512,97024.01.
GlobeNewswire (Europe)
633 Leser
Artikel bewerten:
(2)

Svenska Cellulosa AB: Half-year report, Q2 2024

Finanznachrichten News

January-June 2024 compared with January-June 2023

  • Net sales increased to SEK 9,849m (9,395). The sales increase was mainly as a result of higher delivery volumes due to a gradual ramp up of production at mills where strategic capital expenditures have recently been made.
  • EBITDA amounted to SEK 3,484m (3,755). Lower selling prices were offset by higher delivery volumes, positive exchange rate effects and effective cost control.
  • EBITDA margin was 35.4% (40.0).
  • Operating profit declined to SEK 2,438m (2,825).
  • Operating cash flow amounted to SEK 1,203m (1,851).
  • Earnings per share was SEK 2.49 (3.06).

April-June 2024 compared with April-June 2023

  • Net sales increased to SEK 5,291m (4,582), mainly attributable to higher selling prices and higher delivery volumes.
  • EBITDA amounted to SEK 1,888m (1,700) and EBITDA margin was 35.7% (37.1). Higher selling prices had a positive impact on earnings.

April-June 2024 compared with January-March 2024

  • Net sales increased to SEK 5,291m (4,558), mainly attributable to higher selling prices and higher delivery volumes.
  • EBITDA increased to SEK 1,888m (1,596) and EBITDA margin was 35.7% (35.0). The increase was primarily attributable to higher selling prices.

KEY FIGURES

Quarter

Jan-Jun

SEKm

2024:2

2023:2

%

2024:1

%

2024

2023

%

Net sales

5,291

4,582

15

4,558

16

9,849

9,395

5

EBITDA

1,888

1,700

11

1,596

18

3,484

3,755

-7

EBITDA margin, %

35.7

37.1

35.0

35.4

40.0

Operating profit

1,361

1,229

11

1,077

26

2,438

2,825

-14

Net Profit

960

916

5

789

22

1,749

2,129

-18

Earnings per share SEK

1.37

1.32

1.12

2.49

3.06

Operating cash flow

526

648

677

1,203

1,851

Net Debt / EBITDA (LTM)

1.8x

1.3x

1.8x

1.8x

1.3x


SUMMARY OF THE SECOND QUARTER OF 2024

SCA's earnings for the second quarter were stronger compared with the preceding quarter and the year-earlier quarter. Demand for fiber-based products gradually grew during the first half of the year, which led to progressively higher selling prices that positively impacted earnings. The high rate of self-sufficiency in wood raw material, energy and logistics continued to contribute to effective cost control and the strategic capital expenditures recently made in pulp and packaging paper resulted in higher delivery volumes.

The supply of wood raw material to SCA's industries was stable. The price of sawlogs and pulpwood continued to rise slightly compared with the preceding quarter.

Seasonally stronger demand combined with higher sawlog costs led to increasing selling prices for solid-wood products compared with the preceding quarter.

Demand in the Pulp segment remained at a good level with increased delivery volumes and progressively higher selling prices compared with the preceding quarter.

Demand for packaging material continued to increase during the quarter, leading to stronger demand for kraftliner and progressively higher selling prices compared with the preceding quarter.

Seasonally lower demand for electricity and solid biofuel combined with a weaker market for liquid biofuel led to lower selling prices and delivery volumes in the Renewable Energy segment.

INVITATION TO PRESS CONFERENCE ON HALF-YEAR REPORT 2024

Members of the media and analysts are hereby invited to attend a press conference where this interim report will be presented by the President and CEO, Ulf Larsson, and by the CFO, Andreas Ewertz.

Time: Friday, July 26, 2024 at 10:00 a.m.

The press conference will be webcast live at www.sca.com. It is also possible to participate by telephone by calling:

Sweden: +46 (0)8 505 204 24

UK: +44 (0)33 0551 0200

US: +1 786 697 3501

Specify "SCA Q2".

For further information, please contact

Andreas Ewertz, CFO, +46 (0)60 19 31 97

Josefine Bonnevier, Investor Relations Director, +46 (0)60 19 33 90

Anders Edholm, SVP Sustainability and Communications, +46 (0)60 19 32 12

Please note:

This is information that SCA is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of the contact person set out below, on July 26, 2024 at 8:00 a.m. CEST. The report has been reviewed by the company's auditors.

Anders Edholm, SVP Sustainability and Communications, +46 (0)60 19 32 12



The core of SCA's business is the growing forest, Europe's largest private forest holding. Around this unique resource, we have built a well-developed value chain based on renewable raw material from our own and others' forests. We offer packaging paper, pulp, wood products, renewable energy, services for forest owners and efficient transport solutions. 2022 the forest products company SCA had approximately 3,400 employees and sales amounted to approximately SEK 18 bn. SCA was founded in 1929 and has its headquarters in Sundsvall, Sweden. For more information, visit www.sca.com


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.